News from Demuris

Demuris founder, Prof Jeff Errington, sells previous spin out company Prolysis Ltd

12 November 2009

Prolysis Ltd, the UK leading antibiotic discovery and development company, has been acquired by a major Australian Biotech company, Biota. Prolysis was founded in 1998 by Prof Jeff Errington, whilst he was working in Oxford.

Biota has been a major player in the antiviral drug market and developed zanamivir, which is currently marketed globally by GlaxoSmithKline as the anti-flu drug Relenza.

Jeff has remained associated with Prolysis as a Director, CSO and consultant since the company's inception, and has been offered a position on the Board of Biota.

Press release from Biota Holdings Ltd.

The transition of Prolysis to the drug development phase leaves an opening for a UK antibiotic discovery company, which Demuris is well placed to fill.

Demuris Limited
Newcastle Biomedicine Bio-Incubators,
Faculty of Medical Sciences, Framlington Place,
Newcastle upon Tyne, NE2 4HH, UK

Tel: +44 (0)191 223 5608
Fax: +44 (0)191 223 5609
Email: enquiries@demuris.co.uk

Demuris Limited is registered in England, company number: 06255507

Demuris Limited 2015